TNF and histiocytic sarcoma: Specifically, the monoclonal antibody adalimumab, designed to target tumor necrosis factor (TNF)-α, demonstrated effectiveness compared to a placebo in two phase III trials, and for several years was the only biologic drug approved by the Food and Drug Administration (FDA) for the treatment of HS [15].